{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:24:00Z","timestamp":1791181440089,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"3-4","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.bcmd.2012.06.004","type":"journal-article","created":{"date-parts":[[2012,7,19]],"date-time":"2012-07-19T00:48:14Z","timestamp":1342658894000},"page":"170-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications"],"prefix":"10.1016","volume":"49","author":[{"given":"Sandra","family":"Malak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Saint-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bellanne-Chantelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Najman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2012.06.004_bb0005","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","article-title":"Polycythemia vera: myths, mechanisms, and management","volume":"100","author":"Spivak","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0010","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0015","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0020","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0025","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0030","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0035","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders","volume":"355","author":"Campbell","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0040","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0045","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0050","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0055","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ng.341","article-title":"A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms","volume":"41","author":"Olcaydu","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0060","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.342","article-title":"A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms","volume":"41","author":"Kilpivaara","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0065","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms","volume":"41","author":"Jones","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0070","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood-2005-12-4852","article-title":"Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders","volume":"108","author":"Bellanne-Chantelot","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0075","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1365-2141.2005.05683.x","article-title":"The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera","volume":"130","author":"Cario","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0080","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/cncr.22240","article-title":"JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders","volume":"107","author":"Rumi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0085","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1182\/blood-2005-12-4988","article-title":"Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders","volume":"107","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0090","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1182\/blood-2003-03-0885","article-title":"Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease","volume":"102","author":"Kralovics","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0095","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2008-03-143602","article-title":"Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden","volume":"112","author":"Landgren","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0100","first-page":"2427","article-title":"Familial Vaquez's diseases","volume":"79","author":"Tursz","year":"1971","journal-title":"Presse Med."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ajh.2830160407","article-title":"Increased prevalence of polycythemia vera in parents of patients on polycythemia vera study group protocols","volume":"16","author":"Brubaker","year":"1984","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0110","first-page":"159","article-title":"Epidemiological data in polycythaemia vera: a study of 842 cases","volume":"40","author":"Najean","year":"1998","journal-title":"Hematol. Cell Ther."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0115","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1200\/JCO.2007.12.6896","article-title":"Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation","volume":"25","author":"Rumi","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0120","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2009-01-197525","article-title":"Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms","volume":"114","author":"Saint-Martin","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0125","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3324\/haematol.2010.034488","article-title":"The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms","volume":"96","author":"Olcaydu","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0130","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0135","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","article-title":"Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors","volume":"81","author":"Wolanskyj","year":"2006","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0140","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0145","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms","volume":"118","author":"Vainchenker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1054\/blre.2001.0158","article-title":"Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management","volume":"15","author":"Tefferi","year":"2001","journal-title":"Blood Rev."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0155","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0160","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.1999.17.9.2954","article-title":"Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines","volume":"17","author":"Barosi","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0165","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk","year":"1986","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0170","first-page":"177","article-title":"Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group","volume":"23","author":"Murphy","year":"1986","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0175","first-page":"29","article-title":"Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment","volume":"34","author":"Murphy","year":"1997","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0180","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0185","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0190","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/hon.863","article-title":"Familial chronic myeloproliferative disorders: the state of the art","volume":"26","author":"Rumi","year":"2008","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0195","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0200","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","article-title":"Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients","volume":"93","author":"Passamonti","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0205","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0210","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0215","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0220","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0225","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bjorkholm","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0230","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0235","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0240","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/10428190802688152","article-title":"JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients","volume":"50","author":"Palandri","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0245","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0250","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","article-title":"Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias","volume":"70","author":"Abdel-Wahab","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0255","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis","volume":"108","author":"Lacout","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0260","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-12-257063","article-title":"Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice","volume":"116","author":"Marty","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0265","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2005-09-3826","article-title":"Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders","volume":"107","author":"Passamonti","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0270","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0275","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.exphem.2009.06.006","article-title":"JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera","volume":"37","author":"Carobbio","year":"2009","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bcmd.2012.06.004_bb0280","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal","volume":"22","author":"Vannucchi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2012.06.004_bb0285","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1100\/tsw.2011.108","article-title":"Defining the thrombotic risk in patients with myeloproliferative neoplasms","volume":"11","author":"Vianello","year":"2011","journal-title":"Sci. World J."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979612001283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979612001283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:28:58Z","timestamp":1761049738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979612001283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":57,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S1079979612001283"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2012.06.004","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2012.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}